Prospective observational study evaluates DELFI-TF for monitoring treatment response in metastatic colorectal cancer, suggesting improved assessment methods.
Key Points
The study aims to assess the clinical value of DELFI-TF in monitoring treatment response compared to traditional CT imaging in metastatic colorectal cancer.
Prospective observational substudy of the Dutch Colorectal Cancer Cohort.
Longitudinal collection of blood samples alongside routine CT imaging.
Assessment of ctDNA levels using the DELFI-TF assay.
Analysis of ddPCR samples from patients with confirmed RAS or BRAF mutations.
Exploration of various endpoints related to ctDNA dynamics and treatment response.
504 patients were enrolled, with 2186 blood samples matched to corresponding CT scans.
The majority of blood samples were collected within 14 days of CT imaging.
Comprehensive demographic and clinical data will be presented, supporting ongoing evaluation until 2026.
The study aims to establish DELFI-TF's potential as a complementary tool for treatment monitoring.